Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed cancer of the nasopharynx based on biopsy of a primary lesion and/or lymph nodes~  * Histologic WHO types I-IIb/III~* Stage IIB-IVB disease~  * No T1-2, N1 disease in which node positivity is based on the presence of retropharyngeal lymph nodes~* No distant metastases~* Zubrod performance status 0-1~* WBC ? 4,000/mm?~* Hemoglobin ? 9.0 g/dL~* Platelet count ? 100,000/mm?~* Absolute neutrophil count ? 1,500/mm?~* INR ? 1.5~* aPTT ? 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase ? 1.5 times ULN~* ALT and AST ? 1.5 times ULN~* Bilirubin ? 1.5 times ULN~* Creatinine ? 1.5 mg/dL OR creatinine clearance ? 55 mL/min~* Urine protein:creatinine (UPC) ratio \< 1.0~  * If UPC \> 0.5, 24-hour urine protein must be \< 1,000 mg~* Hearing loss primarily sensorineural in nature and requiring a hearing aid or intervention that interferes in a clinically significant way with activities of daily living allowed~* Conductive hearing loss from tumor-related otitis media is allowed~* No severe, active comorbidity, including any of the following:~  * Ongoing bleeding diathesis, hemorrhagic disorder, or coagulopathy within the past 6 months~ * Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months~ * Esophageal varices, nonhealing wound, nonhealing ulcer, or bone fracture within the past 6 months~ * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within the past 30 days~ * Unstable angina and/or congestive heart failure or peripheral vascular disease requiring hospitalization within the past 12 months~ * Major medical or psychiatric illness that, in the opinion of the study investigator, would preclude study compliance~ * Active, untreated infection and/or acute bacterial or fungal infection requiring intravenous antibiotics~ * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects~ * History of significant weight loss (\> 15% from baseline)~ * History of arterial thromboembolic events~ * Acquired immune deficiency syndrome~ * Transmural myocardial infarction~ * Cerebrovascular accident~ * Transient ischemic attack~ * Any other cardiac condition that, in the opinion of the investigator, would preclude study compliance~* No gross hemoptysis or hematemesis, defined as bright red blood of ? 1 teaspoon per coughing episode, within the last 4 weeks (incidental blood mixed with phlegm allowed)~* No other invasive malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the breast, oral cavity, or cervix~* Nutritional and physical condition considered suitable for study treatment~* No significant traumatic injury within the past 4 weeks~* No history of allergic reaction to the study drugs~* No baseline blood pressure \> 150/100 mm Hg~* No peripheral neuropathy ? grade 2~* Not pregnant or nursing~* Negative serum pregnancy test~* Fertile patients must use effective contraception during and for ? 6 months after completion of study treatment~* At least 10 days since prior and no concurrent dipyridamole, ticlopidine, clopidogrel bisulfate, cilostazol, warfarin, heparin, daily treatment with acetylsalicylic acid (\> 325 mg/day), or nonsteroidal anti-inflammatory medications known to inhibit platelet function~* No prior head and neck surgery of the primary tumor or lymph nodes except for incisional or excisional biopsies~  * More than 15 days since prior biopsies~* More than 1 week since prior fine-needle aspirations or placement of percutaneous gastrostomy tube~* More than 4 weeks since prior major surgical procedures~* No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields~* No prior bevacizumab or other vascular endothelial growth factor-targeting agents~* No prior systemic chemotherapy for the study cancer~  * Prior chemotherapy for a different cancer allowed~* No concurrent hematologic growth factors (e.g. filgrastim \[G-CSF\], darbepoetin alfa, epoetin alfa) during study chemoradiotherapy~* No concurrent prophylactic growth factors for neutropenia during study adjuvant therapy~* No concurrent prophylactic amifostine or pilocarpine~* No other concurrent experimental therapeutic cancer treatments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (bevacizumab, cisplatin, fluorouracil, IMRT, 3D-CRT) (Type: EXPERIMENTAL): BEVACIZUMAB AND CHEMORADIOTHERAPY: Patients receive bevacizumab IV over 30-90 minutes and cisplatin IV over 20-30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 1, patients also undergo three-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for a total of 33 fractions.~ADJUVANT THERAPY: Beginning in week 10, patients receive fluorouracil IV continuously over 96 hours on days 1-4, cisplatin IV over 20-30 minutes on day 1 OR days 1 and 2, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).